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Background: Patients with plasma cell dyscrasias are at an increased risk for infections 
due to their dysfunctional immune system. Each year these vulnerable patients are 
advised to receive the flu shot, but this vaccine has been shown to induce a serologic 
response that is not sufficiently protective in these patients. More effective methods for 
vaccinating patients with plasma cell dyscrasias are necessary.  
 
Methods: The Study of High-Dose Influenza Vaccine Efficacy by Repeated dosing IN 
Gammopathy patients (SHIVERING 1) Pilot Trial was implemented at the Yale Cancer 
Center during the 2014-2015 flu season. Patients with plasma cell dyscrasias (n=51) 
received the high-dose inactivated trivalent influenza vaccine followed by a booster dose 
of that same vaccine 30 days later. The SHIVERING 2 randomized, double-blind, 
placebo-controlled, interventional trial was implemented at the Yale Cancer Center 
during the 2015-2016 flu season. The experimental arm (n=81) received the two dose 
regimen and the control arm (n=41) received the standard of care. In both trials, patients 
were followed throughout the flu season for evidence of flu infections, and sera was 
collected for hemagglutinin titer analysis and correlation with clinical characteristics and 
patient demographics. 
 
Results: SHIVERING 1 demonstrated that the double high-dose regimen was safe and 
resulted in significantly higher rates of seroprotection than have been previously reported. 
There were no grade ³ 2 adverse events. The seroprotection rate increased from 4% at 
baseline, to 47% after the first vaccine, and to 65% after the second vaccine. 
SHIVERING 2 demonstrated significantly higher rates of seroprotection at day 60 and a 
lower rate of laboratory confirmed flu infections in the experimental arm versus the 
control arm. Analysis of the durability of serologic protection demonstrated a significant 
difference in HAI titer growth and direction between the two arms, with the standard of 
care arm experiencing a decline in HAI titer levels during the day 30 to day 60 interval 
following vaccine administration. Additionally, patients with early disease in the 
experimental arm were significantly more likely to remain seroprotected at study end 
than patients with advanced disease in the control arm. Finally, patients that are female 
and those that had undergone an autotransplant in the past were significantly more likely 
to remain seroprotected at study end.    
 
Conclusion: These trials suggest that a boosted high-dose influenza vaccine regimen is 
safe and results in lower rates of infection and higher rates of seroprotection in patients 
with plasma cell disorders. Patients with early stage disease are able to mount a more 
durable serologic response than patients with advanced disease. Larger studies will be 
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This investigation attempts to answer a very simple question: can we improve 
how we vaccinate against the flu in patients with multiple myeloma and other plasma cell 
dyscrasias? To answer that question, we embarked on the Study of High-dose Influenza 
Vaccine Efficacy by Repeated dosing IN Gammopathy patients – the S.H.I.V.E.R.I.N.G. 
Trials. This investigation began in September of 2014 and continues today. 
Multiple Myeloma 
Multiple myeloma is a neoplastic plasma cell disorder characterized by the clonal 
proliferation of plasma cells in the bone marrow, monoclonal protein in the blood, and 
the systemic organ dysfunction that is caused by this neoplastic process.1 The disease 
accounts for 1% of all cancers and 13% of hematologic cancers. In Western countries, its 
age-adjusted incidence is 5.6 cases per 100,000 persons. This neoplastic process occurs 
across a wide range of ages: the median age at diagnosis is 70 years, but 37% of patients 
are younger than 65 years and another 37% are 75 years or older at diagnosis.2 Despite 
significant improvements in treatment options – autologous stem cell transplantation and 
the development of the next generation of anti-cancer chemotherapies – in patients 
presenting at age 60 years or younger, the 10-year survival rate is 30%.3  
The disease is thought to begin by a premalignant process whereby plasma cells 
proliferate but the host remains asymptomatic. This stage is known as monoclonal 
gammopathy of undetermined significance, or MGUS. The host then progresses, due to 
both genetic mutations and environmental influences, to smoldering myeloma and then to 
symptomatic myeloma. Patients are diagnosed based on the presence of at least 10% 




Once diagnosed, patients are classified as either asymptomatic or symptomatic, 
depending on the presence of related organ or tissue dysfunction. This most often takes 
the form of hypercalcemia, renal insufficiency, anemia, and bone disease. The C.R.A.B. 
acronym for these sequelae of multiple myeloma has been passed on to patients and the 
medical students who study them for decades. A patient’s progress is then further 
delineated in parallel with their signs and symptoms using a staging system based on 
serum β 2-microglobulin, serum albumin, and the presence of high- or low-risk 
chromosomal abnormalities. 
Treatment of symptomatic myeloma, or “active disease,” begins immediately. 
Asymptomatic myeloma is clinically observed, as no benefit comes from treatment with 
conventional chemotherapy.4 The treatment algorithm for patients with active disease is 
dependent on their age and stage, and consists of six main types of treatment: 
immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, traditional 
chemotherapies, corticosteroids, and stem cell transplantation.5 The medical team and the 
patient together balance the benefits of each piece of this arsenal against their associated 
side effects. This is a disease that cannot be cured, but only managed. 
Risk for Infections Multiple Myeloma 
Part of that yearly management comes in the form staying otherwise healthy. 
Infections are a significant cause of morbidity and a leading cause of death in patients 
with multiple myeloma. Immunologically, this makes sense: those with a cancer of the 
immune system have a dysfunctional defense in place that is further weakened by 
immunosuppressive chemotherapies and steroids. These patients represent a near-perfect 




cell immunodeficiency in the host, leaving the patient vulnerable to viral (influenza, 
CMV, VZV, HSV), fungal, and mycobacterial infections. Constant transfusions can lead 
to iron overload, creating an environment in which all bacteria thrive, but aspergillus and 
zygomycetes feel particularly at home. Defects in the complement cascade and functional 
hypogammaglobulinemia put the host at risk for infections by the encapsulated bacteria. 
The severe neutropenia induced by rounds of chemotherapy leaves the host open to 
infection by both gram negative and gram positive bacteria.6 Similar to the progression of 
opportunistic infections seen in patients with HIV/AIDS, bacterial infections with 
Streptococcus pneumonia, Haemophilus influenza and Escherichia coli predominate in 
the early stages of the disease and then give way to viral and fungal infections as the 
myeloma advances.7 It is no surprise that if a patient with multiple myeloma presents 
with a fever, they are to be considered infected until proven otherwise.  
A study of population-based data from Sweden comparing all patients diagnosed 
with multiple myeloma between 1988 and 2004 (n = 9,253) to 34,931 matched controls 
quantified the exact increased risk for infection.8 Overall, patients with multiple myeloma 
had a seven-fold (hazard ratio = 7.1; 95% C.I. = 6.8-7.4) risk of developing any type of 
infection compared to matched controls. Multiple myeloma patients had the same seven-
fold (hazard ratio = 7.1; 95% C.I. = 6.8-7.4) risk of developing a bacterial infection and a 
ten-fold (hazard ratio = 10.0; 95% C.I. = 8.9-11.4) risk of developing a viral infection. At 
one year follow up, infection was the cause of death in 22% of patients. A separate study 
of over 3,000 patients with multiple myeloma that investigated early deaths (within the 




These studies could change the acronym of multiple myeloma sequela from C.R.A.B. to 
the more appropriate, “C.R.A.B.I.,” with an “I” for “infection.”  
In addition to the risk that these infections pose to the immunocompromised 
patient, the inflammatory response that follows the infection, particularly in the bone 
marrow microenvironment, may contribute to the progression of the host’s multiple 
myeloma. Similar to how HPV can lead to cervical cancer, research has focused on 
finding a viral trigger of multiple myeloma, with HHV-8 as the prime suspect.10 The tie 
between inflammation and cancer initiation and progression has been well-studied, while 
the tie between inflammation and initiation or progression of multiple myeloma remains 
an exciting area of current research.11 A recent study by the Dhodapkar lab investigated 
the chronic inflammation caused by specific lipid subtypes as a trigger for multiple 
myeloma in a mouse model of Gaucher disease, a disease associated with higher rates of 
multiple myeloma.12 Other studies have examined and illustrated differences in toll-like 
receptor (TLR) expression in these neoplastic plasma cells, providing further molecular 
evidence that inflammation and the body’s innate immune response following an 
infection is key to driving the hospitable microenvironment in which multiple myeloma 
thrives.13 Put simply, infections drive inflammation and inflammation drives multiple 
myeloma. It is thus no wonder that these studies call for a greater focus on improving 
treatment of and prophylactic measures against infections in this vulnerable population. 
The Influenza Vaccine 
Vaccine prophylaxis against the influenza virus in patients with multiple myeloma 
and other plasma cell dyscrasias provided the basis for this current investigation. The 




United States. The severity of disease varies year by year, and the Center for Disease 
Control (CDC) estimates that the flu is the cause of between 9,200,00 to 35,600,000 
illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths each year.14 A 
2007 study by Molinari et al. calculated the total annual economic burden of the 
influenza virus to be $87 billion.15 The influenza virus is an RNA virus that has three 
main subtypes – A, B, and C. The various subtypes of A and B are the main cause of the 
annual flu epidemic and the targets that the influenza vaccines attempt to protect against.  
The World Health Organization (WHO) and the Center for Disease Control 
(CDC) recommend yearly vaccination against the influenza virus for all people over the 
age of 6, with rare exception. The vaccine that the vast majority of people receive is an 
inactivated mixture of the likely circulating viruses for that year. More specifically, each 
year the vaccine includes a recent H1N1 virus, a recent H3N2 virus (both of which are A 
viruses), and an influenza B virus. Together these three form the “trivalent” vaccine. The 
vaccine induces the production of antibodies against the viral attachment protein 
hemagglutinin, thus inhibiting viral entry and neutralizing the virus. 16  The serum 
hemagglutinin-inhibition (HAI) assay is the means by which one can assess the HAI 
antibody response to the influenza vaccine. Higher levels of HAI antibody are correlated 
with clinical protection against influenza virus infection.17 The target seroprotection rate, 
defined as the proportion of individuals who achieve an HAI titer of >1:40, is accepted to 
be >70% in the healthy population. Yet this target protection rate is not always achieved 
with the current regimen or, more often, the vaccine simply misses the target and protects 
hosts against the incorrect subtypes. Each year the CDC reports whether it was a “good” 




confidence in the current trivalent approach. A recent meta-analysis of pooled influenza 
vaccine effectiveness (VE) (the percent reduction of disease in the vaccinated group 
compared with the unvaccinated group) concluded that “vaccine improvements were 
needed.” Pooled VE was 33% for H3N2, 54% for type B, and 67% for the H1N1 
subtype.18 Given the yearly disease burden and the sub-optimal accuracy of the vaccine 
each year, much work has been done to improve the traditional single, trivalent 
inactivated influenza vaccine regimen. 
As our current influenza season approaches, experts in the United States are 
watching the southern hemisphere with great anxiety. Experts pay particularly close 
attention to Australia, the last stop for the approaching influenza strain on route to North 
America. Australia has experienced a record-high number of laboratory-confirmed 
influenza notifications and higher-than-average numbers of hospitalizations and deaths. 
By mid-October, toward the end of the Australian flu season, notifications had reached 
215,280, far greater than the 59,022 cases reported during the 2009 H1N1 influenza 
pandemic, with the influenza A (H3N2) subtype the predominate subtype. 19  The 
preliminary estimate of vaccine effectiveness against this H3N2 subtype was a mere 
10%. Unfortunately, it is likely the 2017 influenza season will highlight the need for 
improved accuracy and efficacy in our influenza vaccine development process. 
Vaccine Durability 
In addition to the question of vaccine accuracy, there is also the key question of 
vaccine durability: how long does the serologic response last and is the patient protected 
for the entire flu season? Antibody titers decline over time, but does that decline matter 




protection? After matching the vaccine with the circulating strains, the immunization 
process must then be timed to optimize serologic protection during a flu season that 
occurs with variability between November and April. Many studies have looked at the 
durability of the serologic response to both flu infection and the flu vaccine. Durability of 
serologic defense is determined by both host and vaccine characteristics. Key host factors 
include age, comorbidities, and prior exposure to the antigen or the vaccine. Key vaccine 
characteristics include mode of delivery and type of vaccine (live attenuated, inactivated, 
subunit, or toxoid). Live attenuated vaccines are known to produce a more robust and 
durable immunity, as these vaccines activate memory B cells, memory helper T cells and 
memory killer T cells. The downside is that live attenuated vaccines are, as their name 
suggests, alive. Inactivated vaccines, the most commonly administered version of the flu 
vaccine, pose no danger of infection but do not stimulate as robust or durable an immune 
response, and therefore often require booster vaccines to induce a truly protective 
response.  
The 1918 H1N1 influenza virus pandemic (the “Spanish Flu”) killed over 50 
million people worldwide and survivors of that pandemic still possess, over 90 years 
later, highly-functional, virus-neutralizing antibodies to that historically aggressive 
virus.20 Not nearly as immunogenic as this strain, the modern influenza vaccine takes 2-4 
weeks to illicit seroprotection that will peak at 4-6 weeks and last for 6-12 months in 
adults. However, this durability has been called into question, most notably in the elderly, 
a population most at risk for influenza infection and related complications. From 1990 to 
2006, advisory committees in the United States and Canada advised that providers delay 




“antibody levels may fall below protective levels within 4 months” in these patients.21 A 
2008 meta-analysis of this claim that, “Influenza vaccine induced antibody decline more 
rapidly in the elderly, falling below seroprotective levels within 4 months” found, “no 
compelling evidence for more rapid decline in the elderly as compared with young 
adults.” 22 In response to this work and similar findings, the advisory committee 
abandoned their advice to delay vaccination. The titer decline rate for patients with 
multiple myeloma or other immunocompromising illnesses is not currently known, and 
should be investigated. Although the elderly may remain protected throughout the entire 
flu season, it is possible that patients with multiple myeloma are unable to mount a truly 
robust or sufficiently durable response to the vaccine, and are left vulnerable for the 
second half of the flu season or longer. 
Strategies to Improve Vaccine Efficacy 
Much work has been done in recent decades to improve on our current lackluster 
defense against the flu. The studies that aim to improve protection against the flu that are 
most relevant to this investigation include the development of a “high-dose” vaccine and 
the addition of a second “booster” vaccine to increase HAI antibody titer levels. The 
high-dose, trivalent inactivated influenza vaccine, known as Fluzone High-Dose and 
produced by Sanofi, contains four times the hemagglutinin as the standard dose vaccine. 
It was first licensed in 2009, and in 2014 a multi-center, randomized, double-blind, 
active-controlled trial compared the high-dose (HD) vaccine to the standard dose (SD) 
vaccine in 31,989 patients over the age of 65 years with laboratory-confirmed influenza 
illness as the primary endpoint.23 The HD group had lower rates of infection versus the 




and seroprotection rates. This study established the high-dose vaccine as the standard of 
care for patients over the age of 65.  
The idea of using a first vaccine to prime the immune system followed by a 
booster vaccine to spark antibody production is not new and has historically been applied 
to pediatric patients. The CDC recommends that all children who have not been 
vaccinated against the flu in the past receive this two dose, or “prime-boost” regimen.24 
This booster regimen has since gained momentum for use with other vulnerable 
populations. Both patients that are positive for HIV and hemodialysis patients have been 
shown to benefit from a boosted influenza vaccine regimen.25,26 However, a recent meta-
analysis showed no clinical benefit to this practice in patients on hemodialysis.27 A third 
actively-researched approach to improving the influenza vaccine involves the addition of 
an adjuvant to the antigen in an attempt to increase the immunogenicity of the vaccine. 
As Sanofi pursued the high-dose approach, Novartis developed the M59 adjuvanted 
vaccine that has shown some promise in the elderly population.28 The goal of using an 
adjuvanted protein is to aim the vaccine at a less fickle target and proteins that do not so 
rapidly undergo genetic drift. Along with many other strategies, these novel approaches 
continue to fuel the search for a better flu vaccine. 
Vaccine Efficacy in Patients with Multiple Myeloma 
Even in the face of these developments, the current standard of care fails to 
protect patients with multiple myeloma. Their dysfunctional immune systems leave them 
unable to effectively defend against the flu or mount a sufficient response to the vaccine. 
Several recent studies have examined the efficacy of vaccinations in patients with 




seroprotection rates 4-6 weeks following vaccination against influenza, streptococcus 
pneumonia and haemophilus influenza in 52 patients with multiple myeloma. At 4-6 
weeks post-vaccination only 19% of patients reached protective HAI antibody titer levels. 
Response to the Pneumovax II vaccine against streptococcus pneumonia was also weak, 
as 39% of patients had low titers following vaccination. Response to the heamophilus 
influenza vaccine was statistically no different from the healthy population. 29  More 
recently, investigators have begun to trial the novel regimens described above in patients 
with multiple myeloma. 
A recent retrospective study examined the immune response of a single dose 
versus boosted influenza vaccination in patients with multiple myeloma.30 The secondary 
aim of the trial was to correlate this immune response with multiple myeloma parameters 
and myeloma treatment regimens. In 48 patients with smoldering or active myeloma, a 
single dose of the standard influenza vaccine resulted in a seroprotection of 14.6%. The 
rate of seroprotection more than doubled to 31.3% after a second dose of the standard 
vaccine 4 weeks later, representing a statistically significant improvement. The trial study 
concluded that, “There are no systemic studies on the efficacy of influenza vaccines in 
patients with multiple myeloma. Double vaccination against influenza in multiple 
myeloma patients seems to enhance protection and should be systematically studied. A 
larger and stratified cohort of patients would be needed for systematic assessment of 
associations between immunization results and clinical parameters.”  
The goal of the SHIVERING Trials was to do this systematic assessment of a 
novel influenza vaccination regimen in patients with multiple myeloma and other plasma 




population. The current regimen does little to protect these patients against that threat. 
Even with only the current resources available, we can do better for these patients. 
SHIVERING I, a safety trial, and SHIVERING II, a randomized, double-blind, placebo-
controlled clinical trial, aimed to do better by investigating a novel vaccine regimen: the 
Fluzone High-Dose influenza vaccine at day zero followed by that same high-dose 





















STATEMENT OF PURPOSE AND HYPOTHESES 
The purpose of this investigation is to test a novel influenza vaccine regimen in 
patients with multiple myeloma, and to better define the nature of their response to this 
vaccine. If this regimen improves clinical outcomes and serologic protection it should be 
further studied and should be considered for the standard of care in this select group of 
patients.  
The aim of this investigation is to trial a novel influenza vaccine regimen in 
patients with multiple myeloma and other plasma cell dyscrasias to determine the rates of 
flu infection, the levels of serologic protection against the flu, the durability or lasting 
nature of that defense, and to find clinical characteristics of these patients that correlate 
positively or negatively with response to this vaccine regimen. 
I hypothesize that the durability of the serologic protection – how long patients 
remain seroprotected throughout the flu season – will correlate positively with the rise in 
titer level during the day 30 to day 60 time interval and will correlate negatively with 
disease stage and number of previous anti-cancer therapies. I hypothesize that this 
vaccine regimen will be safe and well-tolerated by all patients in the study. I hypothesize 
that the high-dose plus a booster strategy will result in lower rates of clinically diagnosed 
influenza, higher rates of serologic protection, and that an improved serologic response to 
the vaccine will correlate with more mild stages of myeloma and less aggressive stages of 







Statement on Personal Contribution 
I joined the SHIVERING trial team during the fall of my second year of medical 
school at the invite of Andrew Branagan MD, a hematology-oncology fellow at Yale in 
the Clinical Scholars Program. Dr. Branagan, with Dr. Dhodapkar as senior PI, led the 
SHIVERING Trials throughout the 2014-2015 and 2015-2016 flu seasons. As a sub-
investigator, my primary roles included screening and consenting patients, helping to 
process the daily flow of patient sera, and EPIC chart reviews and data acquisition on 
each patient’s demographics, influenza history, disease status and treatment history. 
Following each trial, I was intimately involved with analysis of the results, manuscript 
writing and poster and oral presentations of these results at academic conferences. The 
background research, data collection, and statistical analysis of the question of durability 
of serologic protection was done independently, as was the writing of this thesis. My 
work on the SHIVERING trials was done in parallel with my academic coursework at the 
schools of Medicine and Management over the last four years. The work on durability of 

























1. To study the rate of disease control throughout the study period as determined by 
lack of disease progression requiring new or different therapy. 
 




1. To study the rate of influenza-related morbidity and mortality at the end of the flu 
season following the high-dose booster strategy. 
 
2. To study the rates of serologic protection (defined as HAI titer > 40) following 
each interval of the high-dose booster regimen. 
 
3. To study preliminary correlations between serologic protection and clinical 






1. To study the influenza infection rate between patients who receive the high-dose 
booster regimen and those that receive the standard of care. 
 
2. To study the rate of disease progression determined by lack of disease progression 
requiring new or different therapy in patients who receive the high-dose booster 




1. To study the rates of serologic protection (defined as HAI titer > 40) following 
each interval and between both the experimental and control groups. 
 
2. To study the durability of serologic protection to better define the endurance of 
the standard of care in this patient population and determine the impact of the 













Clinical Trial Design 
The SHIVERING I trial was implemented from September 2014 through May 
2015 at the Yale Cancer Center. Patients were eligible for inclusion in the study if they 
were (1) able to understand and sign the informed consent form, which was provided in 
by English and Spanish, (2) greater than 18 years of age at the start of the study, and (3) 
had a diagnosis of a monoclonal gammopathy: asymptomatic or active multiple myeloma 
(MM), asymptomatic or active Waldenstrom Macroglobulinemia (WM), or Monoclonal 
Gammopathy of Undetermined Significance (MGUS). Patients were deemed ineligible 
for inclusion in the study if they (1) had already received the influenza vaccine that year, 
(2) had an egg allergy or (3) were pregnant or planning to become pregnant during the 
study period. All patients in the study, regardless of age, received the study intervention 
of one dose of the trivalent Fluzone High-Dose influenza vaccine followed by a second 
dose of that same vaccine thirty days later. Blood samples were taken from each patient 
before the first vaccine at day 0, before the second vaccine at day 30, and 30 days after 
the second vaccine at day 60.  
Study Oversight 
The study was approved by the Yale School of Medicine Institutional Review 
Board and conducted in accordance with the International Conference on Harmonization 
Good Clinical Practices guidelines. All patients in the trial provided written informed 






The Fluzone High-Dose influenza vaccine (produced by Sanofi) is a trivalent 
inactivated vaccine that is administered intramuscularly. The vaccine contains a total of 
180 µg of influenza virus hemagglutinin, made up of 60 µg from each of the three 
influenza strains chosen that year for the vaccine: the A/California/7/2009 (H1N1) virus, 
the A/Texas/50/2012 (H3N2) virus, and the B/Massachusetts/2/2012 (B) virus. 
HAI Titer Measurements 
Serum was isolated from the whole blood samples within 24 hours of each blood 
draw using a standardized protocol (Appendix 1). HAI assays were performed using a 
standardized protocol (Appendix 2). Using the accepted definitions, seroprotection to the 
influenza virus is defined as achieving an antibody titer of ≥1:40 and seroconversion to 
acceptable protection against the influenza virus is defined as a fourfold increase in the 
antibody titer level. 
Patient Screening and Surveillance During Study Period 
Each patient was screened by their hematologist or a study investigator for 
eligibility for the trial. Each patient’s disease status was assessed and recorded at the first 
visit, as was their most recent quantifiable disease marker (m-spike or serum free light 
chain count). Patient surveillance was a top priority for the study team throughout the 
study period. The flu can go un-diagnosed if the patient does not seek treatment and can 
mimic other illnesses even when patients do seek treatment. Our study endpoint was 
laboratory-confirmed influenza infections and the team therefore needed to keep a very 
close eye on each patient. The team was assisted in this effort by the fact that these 




study visit, each patient was asked to fill out a “Flu Morbidity Screen” (Appendix 3) and 
was reminded to reach out to study team if any worrisome symptoms (fever, fatigue, 
headache, body ache, cough, sore throat) developed before their next visit. In addition to 
the clinical surveillance that took place throughout the study period, the team performed a 
retrospective review of each patient’s medical record to check for (1) a laboratory 
diagnosed influenza infection and (2) to count the number of times each patient had 
contact (in person or by phone) with a clinical provider during the study period. On 
average, each patient in the study had contact with a clinical provider once every 11 days. 
This high regularity of contact gives us assurance that if one of the study patients was ill 
with the flu or with any other illness, the team knew about it. It should be noted that there 
was a large range in the number of contacts, dictated primarily by the patient’s diagnosis 
and progression of their disease. 
Assessment for Adverse Events and Safety 
At each study visit each patient was assessed for any adverse events immediately 
following the administration of the vaccine or in the time since the last vaccine. The 
study team used the National Cancer Institute’s Cancer Therapy Evaluation Program 
Adverse Event Recording System (CTEP-AERS), which grades possible adverse events 
according to attribution (can that event be attributed to the intervention) severity, what 
occurred, and what was the action, therapy and outcome. All adverse events were 
recorded at each visit with the study team.  
Patient Demographics and Clinical Characteristics 
Following the conclusion of the study period, the team performed a chart review 




gender), (2) disease type (immunoglobulin and light chain type), (3) history of flu 
vaccine or laboratory confirmed influenza diagnosis during the previous flu season (2013 
– 2014), (4) disease response to therapy for those patients that received therapy (from 
progressive disease to complete response), (5) treatment regimen (anti-cancer 
chemotherapies, immunomodulatory therapies, and steroids), and (6) autotransplant 
status at the start of the study period.    
Statistical Analysis 
 
The McNamer test, used for paired nominal data sets, was used compare 
seroprotection and seroconversion rates from baseline to after the first vaccine and to 
after the second vaccine. Generalized Estimating Equations were used to correlate the 
binary outcomes (clinical correlates) with seroprotection and seroconversion. For 
statistical analysis of the durability of seroprotection, a simple linear regression model 
was used. All statistical analysis was performed using either Prism 7, STATA or Excel 
and the statistical significance was set at P<0.05m using a two-tailed T-test. 
 
SHIVERING 2 
Clinical Trial Design 
The SHIVERING 2 Trial was implemented from September 2015 to May 2016 
and was a multi-center, randomized, double-blind, placebo controlled trial at the Yale 
Cancer Center and several surrounding satellite care centers. The inclusion and exclusion 
criteria for SHIVERING 2 were the same as for SHIVERING 1, as detailed above. 
Patients were randomized in a 2:1 allocation to the experimental arm and the standard of 




patients in the standard of care arm. Patients in the experimental arm received the 
Fluzone High-Dose influenza vaccine at day 0 and then again at day 30. Patients in the 
standard of care arm received the Fluzone High-Dose influenza vaccine if they were 65 
years of age or older and then a placebo second vaccine at day 30. If they were younger 
than 65 years of age, they received a standard dose of influenza vaccine at day 0 and then 
a placebo second vaccine at day 30. For all patients, regardless of their study arm, the 
study team recorded an assessment of disease status (SPEP and serum free light chains) at 
both day 0 and at their end of study visit in May. For all patients, regardless of their study 
arm, the study team took a research blood draw at day 0 before the first vaccine, at day 30 
before the second vaccine, and 30 days following the second vaccine. Patients in both 
arms were encouraged to participate in an optional day 7 and end of study research blood 
draw. As in SHIVERING 1, at each study visit all patients were assessed for any 
laboratory-confirmed (by direct fluorescent antibody or “DFA”) flu infections, flu-like 
symptoms or illnesses, flu-related hospitalizations or deaths. Additionally, as in 
SHIVERING 1 and described above, at each study visit all patients were assessed for any 
adverse events. 
Study Oversight 
The study was approved by the Yale School of Medicine Institutional Review 
Board and conducted in accordance with the International Conference on Harmonization 
Good Clinical Practices guidelines. All patients in the trial provided written informed 







The Fluzone High-Dose influenza vaccine (produced by Sanofi) is a trivalent 
inactivated vaccine that is administered intramuscularly. The vaccine contains a total of 
180 µg of influenza virus hemagglutinin, made up of 60 µg from each of the three 
influenza strains chosen that year for the vaccine: the influenza H1N1 (A) virus, the 
influenza H3N2 (A) virus, and the influenza B virus. 
The remainder of the methods for SHIVERING 2 (HAI titer measurements, 
patient screening and surveillance, adverse events assessment, patient demographics and 
clinical characteristics, and the statistical analysis) were the same as those performed in 
SHIVERING 1, as outlined above. 
 
RESULTS 
This results section will begin with a highlight of the key findings from the two 
SHIVERING trials and then focuses on an analysis of the durability of the immunologic 
defense produced by this vaccine regimen. 
SHIVERING 1 
The SHIVERING I trial enrolled a total of 51 patients during the 2014-2015 flu 
season. Each patient received two doses of the Fluzone High-Dose influenza vaccine and 
study blood draws were taken at the appropriate dates. Baseline patient demographics are 
summarized in Table 1. The median age of the patients was 65 years old and the trial was 
61% male. Of the 51 patients, 49 had a diagnosis of multiple myeloma and 2 had a 
diagnosis of Waldenstrom macroglobulinemia, with a heavy predominance toward the 




flu infection history, 76% of patients received the flu vaccine the previous year and 6% 
had a laboratory confirmed influenza infection. The majority of patients with active 
disease were on active therapy and on a steroid medication. 




No patients in the study experienced a grade 2 or greater adverse event that was 
attributed to the intervention. The most common side effects were soreness at the 
injection sight, fatigue, and malaise. 
Influenza Infection Rate 
Over the study period, 3 of the 51 total patients developed laboratory-confirmed 
influenza infections. This represents 5.9% (95% CI, 1.2%-16.2%) of study participants, a 
significant decrease from the Center for Disease Control estimate of 20% in this 




HAI Titer Response Rate 
There was a statistically significant increase in seroprotection against all three 
strains from baseline (4%) to after the first vaccine (47%) and from baseline to after the 
second vaccine (65%) (P<0.001, Figure 1). Additionally, there was a statistically 
significant increase in seroprotection against all three strains from after the first vaccine 
to after the second vaccine (P<0.01). There was a statistically significant increase in 
seroconversion from after the first vaccine (39%) to after the second vaccine (55%). The 
seroconversion rate excludes those patients who have seroprotection at the start of the 
study.  
Figure 1: SHIVERING 1 HAI titer response rates at each study point.  
 
Clinical Correlates of Serologic Response 
Figure 2 illustrates those clinical variables that are associated with complete 
seroprotection and seroconversion following the full, boosted regimen. There were three 
variables that were significantly associated with increased odds of seroprotection: (1) 




immunoglobulin (IVIG), and (3) if the patient was diagnosed with the flu one year prior 
to this study. There were four variables that were significantly associated with decreased 
odds of seroprotection: (1) diagnosis with a PCD requiring therapy (vs. asymptomatic or 
MGUS), (2) active therapy with conventional chemotherapy, (3) suppression of 
uninvolved immunoglobulins, and (4) laboratory-confirmed diagnosis of a viral 
respiratory infection other than influenza during the study period. A fifth variable, disease 
response to therapy status of less than a partial response, showed a trend toward 
significance (P=0.07). In total, the study identified these five clinical variables that, even 
with this high-dose boosted regimen, are associated with poor response to the vaccine.  
Figure 2: Clinical correlates of seroprotection against all 3 flu strains. 
 
SHIVERING 2 
The SHIVERING 2 randomized, double-blind, placebo-controlled, interventional 
trial enrolled 122 patients with plasma cell dyscrasias. The patient demographics and 
characteristics are highlighted in Table 2. 41 patients were randomized to receive a single 
standard of care influenza vaccination and 81 patients were randomized to receive two 




participants closely resemble those who participated in SHIVERING 1, save for a slightly 
older and a greater percentage of males than in the pilot trial. 
Table 2: Patient demographics and clinical characteristics. 
 
Safety 
No patients in the study experienced a grade 2 or greater adverse event that was 
possibly attributed to the intervention. The most common side effects were soreness at 
the injection sight, fatigue, and malaise. 
Influenza Infection Rate and HAI Seroprotection Rate 
Significantly fewer patients that received the intervention of two Fluzone High-
Dose vaccines developed laboratory-confirmed influenza versus those patients that 
received a single standard of care vaccine (4.0% vs. 8.3%, P<0.05). This is based off an 
intention-to-treat analysis, which includes all subjects according to their randomization 




There was no significant difference in seroprotection rate at baseline (26.8% in control 
vs. 27.2% in experimental) or at day 30 (73.2% in control and 83.6% in experimental). At 
day 60, the experimental arm had a significantly higher rate of seroprotection than the 
control arm (63.9% in control vs. 87.5% in experimental, P<0.05). At the end of study 
time point, the difference between the two arms was not statistically significant (33.3% in 
control vs. 58.5% in experimental, P=0.07). 
Figure 3: Seroprotection against 3 strains at each time point by study arm. 
 
Clinical Correlates of Serologic Response 
The data revealed those variables that are associated with increased or decreased 
odds of achieving total seroprotection against all three strains at 60 days. Those variables 
significantly associated with increased odds for seroprotection include: the female gender 
(OR 1.84, 1.12-3.02, P=0.02) and a documented flu infection during the previous year 
(OR 2.03, 1.04-3.96, P=0.04). Those variables significantly associated with decreased 




MGUS or asymptomatic disease (OR 0.36, 0.19-0.67, P=0.001), an increase in age of ten 
years (OR 0.75, 0.57-0.98, P=0.04), whether the patient was receiving IVIG treatment 
during the study period (OR 4.54, 1.21-16.99, P=0.02), and whether the patient was 
receiving cytotoxic chemotherapy (OR 0.39, 0.16-0.97, P=0.04). There was a trend 
toward significance for the following variables: an increase in the number of prior 
therapies by one was associated with a greater likelihood of seroprotection (OR 0.83, 
0.68-1.02, P=0.07) and receiving the flu vaccine the year prior was associated with an 
increased likelihood of seroprotection (OR 1.60, 0.97-2.63, P=0.07).  
Durability of Serologic Protection 
SHIVERING 2 included an optional end of study (EOS) blood draw for the 
specific purpose of assessing serologic protection throughout the entire flu season in both 
arms. In total, 56 patients chose to take part in the EOS blood draw and were included in 
the following results. For the following results, “loss of seroprotection” indicates that the 
patient attained seroprotection (HAI≥40) and then lost that protection (HAI<40) by the 
end of the study period. Figure 4 illustrates the percentage of patients in each arm that 
were no longer seroprotected (HAI≥40) at EOS. At EOS, the standard of care arm lost 
seroprotection to all three strains at a higher rate compared to the experimental arm, but 









Figure 4: Loss of seroprotection by EOS by strain and study arm. 
 
Figure 5 illustrates the percentage of patients in each arm, separated by disease 
stage (early versus advanced), that lost seroprotection to each strain at EOS. In both the 
experimental and control arms of the study, patients with advanced disease lost 
seroprotection by EOS at a higher rate. Patients in the advanced control group lost 
seroprotection at a significantly higher rate than patients in the early experimental group 









Figure 5: Loss of seroprotection by strain, disease stage and study arm. 
 
 
Figure 6 illustrates the average percentage change in HAI titer across all three 
strains at each time interval: day 30 to 60, day 60 to EOS, and day 30 to EOS. During the 
day 30 to day 60 interval, the average change in HAI titer level for the experimental arm 
(78.4%) was significantly greater than for the control arm (-8.6%) (P<0.05).  





Figure 7 focuses on the day 30 to day 60 interval and illustrates the percentage 
change in HAI titer during that time interval by strain. During that time interval and 
across all three strains, the average HAI titer level of the experimental arm increased at a 
higher rate than the control arm, with the experimental arm positive in each case and the 
control arm negative or just above zero (1.2%) in each case. None of these comparisons 
were statistically significant. 
Figure 7: Average % Change in HAI titer by strain and arm during the day 30 to 
day 60 time interval. 
 
 
Next, the investigation focused on an estimated peak HAI titer value, rather than 
the change in HAI titer, as a possible indicator of vaccine durability. To estimate the peak 
titer values in a uniform fashion each patient’s day 60 titer was used. Patients in the 
experimental arm had a significantly higher peak HAI titer level (996.2 ± 102.7 vs. 547.1 








Figure 8: Peak HAI Titer Level by Study Arm 
 
Patients that were protected against all three strains at the end of the study had 
significantly higher peak HAI titer levels than patients that lost protection by the end of 
the study (1341 ± 120.1 vs. 285.3 ± 75.72, P<0.0001, Figure 9). 





















































Patients in the experimental arm that were protected at the end of study time point had 
significantly higher absolute peak titer levels than patients in the control arm that were 
not protected (1440 ± 119.4 vs. 166.1 ± 55.78, P<0.0001, Figure 10.) 




There was no significant difference in peak HAI titer level between patients with 


























































Figure 11: Peak HAI Titer by Disease Stage 
 
There was no significant difference in HAI titer levels due to steroid use (979.3 ± 124.5 
not on steroids vs. 660.9 ± 100.6 on steroids, P=0.065) or gender (998.8 ± 121.2 for 
females vs. 715.2 ± 117.5 for males, P=0.096), but there was a significant difference in 
peak titer level between patients who received an autotransplant and those that did not 








































Figure 12: Peak HAI Titer by Autotransplant Status 
 
Next, the investigation focused on statistical correlations between patient 
demographics or clinical characteristics and a loss of seroprotection by the end of the 
study. Figure 13 illustrates the Forest Plot results from a regression analysis of the loss of 
seroprotection against study arm (experimental vs. control), disease stage (early vs. 
advanced), gender, age, detailed diagnosis (active disease vs. asymptomatic disease), 
baseline disease remission status (>partial response to therapy vs. <partial response to 
therapy), number of prior therapies, autotransplant recipient status (yes vs. no), and 
current steroid therapy (yes vs. no). The variables of gender (O.R. 0.25, 0.002–0.49, 
P<0.05) and autotransplant status (O.R. -0.52, -0.9 – -0.14, P<0.01) are statistically 
significant, while the variable disease stage (O.R. 0.51, -0.009–1.02, P=0.054) is trending 


































Figure 13: Clinical correlates with loss of seroprotection at study end. 
 
 
Finally, the investigation focused on statistical correlations between the loss of 
seroprotection at the end of the study period and the following variables: seroprotection 
against all 3 strains at baseline, seroprotection against all 3 strains at day 30, 
seroprotection against all 3 strains at day 60, and the percent change in HAI titer during 
the day 30 to day 60 time interval. Figure 14 illustrates the Forest Plot results for this 
model. The variables for seroprotection against all 3 strains at baseline (O.R. -0.46, -0.7- 
-0.22, P<0.001) and for seroprotection against all 3 strains at day 30 (O.R. -0.59, -1.13--









These clinical trials have investigated a novel vaccine regimen in patients with 
plasma cell dyscrasias. The study reconfigured an old vaccine in a new and novel way, 
and the results show that this regimen could have practice-changing implications in the 
field of myeloma and beyond. In addition to lowering the clinical infection rate, these 
trials have provided key insight into the way in which patients with plasma cell 
dyscrasias respond to vaccines, how the serologic response rises and then falls, and what 
clinical or demographic factors encourage or impede the development of immunologic 
defense over time. 
  The pilot clinical trial was focused on establishing the safety and efficacy of the 
high-dose booster regimen in patients with plasma cell dyscrasias. In this study’s cohort 
of patients, the regimen was safe and well tolerated, with no grade 2 or greater adverse 




dose booster regimen provides improved serologic protection and is associated with a 
significantly lower rate of influenza infection than what is expected with the standard of 
care in this population. After a single dose of the high-dose vaccine seroprotection 
against all three strains increased from 4% to 47%, and after the booster vaccine the 
seroprotection rate increased further to 65%. This high a level of seroprotection against 
all three strains has not been previously recorded and is on par with what most healthy 
adults reach with the standard of care vaccine. Furthermore, the laboratory-confirmed 
infection rate of 6% was significantly lower than expected in this population, suggesting 
a real clinical benefit of this regimen.  
Finally, the correlation of serologic response with demographics and clinical 
characteristics revealed several interesting findings that merit further investigation. This 
study has identified several variables correlated with improved serologic response. 
Patients of the female gender and those that endured a documented flu infection during 
the previous year were at significantly increased odds of attaining seroprotection. An 
infection the previous year may have primed the immune system to respond to the 
vaccine or it is possible a more robust response the year prior made these patients 
serologically closer to seroprotection during the current year. This study has identified 
several variables that correlate with lower odds of reaching seroprotection: active PCD 
diagnosis, increased age, currently on IVIG treatment, and currently on cytotoxic 
chemotherapy. Taken together, these variables suggest that sicker patients are less likely 
to form a serologically robust response to the vaccine regimen.  
Taking a step back, this study raises multiple questions: does everyone need this 




achieve equally favorable results with the current standard of care? Are there some 
patients who will benefit more than others from this regimen? These data suggest that 
sicker patients, those older patients with an active PCD diagnosis that has them on IVIG 
and conventional chemotherapy, need this regimen more and should perhaps be targeted 
to receive this regimen in place of the standard of care. However, this was only a pilot 
trial which was implemented during a particularly benign flu season that saw lower rates 
of flu infection across the country. To truly extract the actionable clinical and scientific 
insights a larger cohort of patients and an experimental, randomized, double blind, 
placebo-controlled, phase 2 trial was necessary. 
SHIVERING 2 was this trial. It provided the opportunity to test the hypotheses 
that the high-dose booster regimen is superior to the standard of care and results in 
improved clinical outcomes, more robust and longer-lasting serologic protection, and that 
healthier patients, as was the case in SHIVERING 1, respond better than sicker patients. 
Once again, the regimen appears to be safe, with no grade two or greater adverse events 
attributed to the vaccine. This is no small point. In an age when vaccines are front page 
news as often for their harm as for their protection the fact that giving patients the high-
dose vaccine plus the booster, a total of eight times the inactivated antigen, did not lead to 
more common or more serious adverse events is a key finding. 
Supporting the findings in the pilot trial, patients in the experimental arm had a 
significantly lower rate of laboratory-confirmed flu infection than patients in the control 
arm. This finding has practice-changing implications: patients who receive the high-dose 




standard of care. A larger trial would be needed to confirm or refute these findings, but 
these results suggest that patients on this regimen get the flu less often. 
A comparison of the HAI seroprotection rates of the control arm and the 
experimental arm demonstrates the serologic impact of the high-dose booster regimen. At 
day 30 there was no significant difference in seroprotection rate, suggesting that the 
single high-dose vaccine, in this case, did not lead to significantly higher titer levels in 
the experimental arm. The booster high-dose vaccine, however, did just that and by day 
60 patients in the experimental arm had significantly higher rates of seroprotection than 
the control arm. This suggests that the booster high-dose vaccine is necessary for the 
regimen to be superior to the standard of care. At the end of the study period, the rate of 
seroprotection was not significantly higher in the experimental arm than in the control 
arm (P=0.07). This possible trend led the team to further investigate the drivers and 
correlates of HAI titer durability. 
Moving on to the durability of the produced serologic defense, the key driver of 
this thesis. As described above, there is little research into how long the flu vaccine 
protects the recipient. Is it the full year? Is it 6 months? Or 3 months? Do those eager 
vaccine recipients, who line up for their shot when it first becomes available in 
September, lose protection by the height of the flu season in January and February? And 
what impacts that durability? Is it age or gender? Is it dependent on the previous flu 
season, either a past infection or previous vaccines? Shockingly little is known about this 
major source of morbidity and mortality around the world each year, and a better 
understanding of the flu vaccine is the best shot at standing up to this yearly scourge. If 




Spanish Flu killed more people than World War I), better vaccines are needed and our 
current vaccination tools must be used with greater dexterity. 
This picture becomes even more interesting when investigating a cohort of 
patients with multiple myeloma and other plasma cell dyscrasias. Even less is known 
about the robustness and durability of serologic defense in these particularly vulnerable 
patients. This analysis of the durability of HAI titer levels sheds some much needed light 
on this important question. Although the data is limited by sample side (only 56 patients 
opted for an end of study blood draw) there still exist several exciting findings in these 
data to report and continue to investigate. 
Figure 4 (page 32) highlights the loss of seroprotection by strain at the end of 
study time point. For each strain and for all three strains combined, the control arm lost 
seroprotection at a higher rate than the experimental arm. This is not surprising, but a key 
point when advocating for the need for this high-dose booster regimen. Additionally, 
these data give rare insight into how the standard of care performs over time in this study 
population. Half of all patients in the control arm lost seroprotection against both Flu A 
(H1N1 and H3N2) strains by the end of study point. This standard of care vaccine, in this 
population, does not appear to withstand the test of (flu season) time. A larger trial is 
necessary to determine if these suggestive findings are significant and clinically 
applicable.   
Figure 5 (page 33) further breaks down this question by highlighting the loss of 
seroprotection against each strain by disease stage: early disease versus advanced disease. 
The data suggests that patients with advanced disease are likely to lose seroprotection 




Flu B protection. These data points are in stark comparison with patients with early 
disease in the experimental arm, which suggests that they form a more long-lasting 
immunity: 11% lost H3N2 protection, 22% lost H1N1 protection, and 11% lost Flu B 
protection. The power and statistical significance of these data are limited by the small 
sample size, but this work represents an initial investigation into which patients lose 
seroprotection and how long it takes them to do so. The most interesting and statistically 
significant finding is in the comparison of advanced-control to early-experimental patient 
groups. The advanced-control patients were significantly more likely to lose 
seroprotection when compared with the early-experimental patients (P<0.05). As 
hypothesized and evident in SHIVERING 1, the healthier the patients the more robust 
and sustainable their response is to the high-dose booster regimen. This finding suggests 
that these healthier patients benefit most from this new regimen. As for the advanced 
patients, other approaches may be necessary. It is possible they may need a vaccine in 
September and then the booster 60 or 90 days later, rather than the 30 day interval 
applied in this regimen. 
Figure 6 (page 33) highlights when and to what extent serologic protection levels 
diverge between the two arms across the study period. The difference in HAI titer change 
between the control and experimental arm was significant during the day 30 to day 60 
interval. The experimental arm had just received its booster and, interestingly, control 
arm HAI titer levels on average already began to decline by 8.6%. As HAI titer levels 
peaked higher on average in the experimental arm than in the control arm, it is not 
surprising or clinically significant that they then declined on average to a greater degree 




change for each strain, to reveal any differences in the serologic responses to each strain 
during that key time internal. Each strain showed a large jump in HAI titer average, with 
H1N1 increasing the most (115.7%). Likely due to the high variances and small data set, 
none of these comparisons were statistically significant. Once again, however, this 
analysis gives interesting insight into the serologic durability of the standard of care. In 
this study, during this key time interval, when HAI titer levels of the experimental arm 
are on average rising, those of the control arm are flat or in decline. 
The analysis of how peak titer level predicts serologic durability revealed several 
interesting findings. Peak titer level is more indicative of durability than percent change 
in titer level and likely more practical, as it represents an absolute rather than relative 
value. The findings in Figures 8, 9 and 10 are not surprising: patients that received the 
high-dose booster regimen had significantly higher peaks and the higher the peak the 
higher the likelihood of a durable defense. The higher the peak the further it has to fall 
and the longer the patient remains protected. What is more interesting is determining who 
can produce those higher peaks. These data illustrate that gender and steroid status do not 
have a significant impact on peak titer, but a history of an autotransplant is associated 
with the ability to produce a high peak titer level. This is consistent with the finding in 
Figure 13 that illustrates the protective impact of an autotransplant on loss of 
seroprotection by the end of the study. These findings on the role of peak titer levels 
could have clinical significance in the future. If confirmed, it may make sense to give an 
initial vaccine, check the titer level 60 days later, and give a booster vaccine if the titer 




protective in this process and a booster vaccine may deserve consideration in those 
patients that have not undergone such a procedure. 
Similar to the analysis of SHIVERING 1 looking at the clinical correlates of 
seroprotection, Figures 13 (page 39) and 14 (page 40) examine the clinical correlates of 
serologic durability.  The finding of the impact of gender is quite interesting and suggests 
that male patients are significantly more likely to lose seroprotection than female 
patients, controlling for other considered variables. This finding is consistent with the 
literature, as it has been shown that in older individuals there are differences between the 
genders in response to the influenza, tetanus, pertussis, shingles, and pneumococcal 
vaccines. 31  Crediting the impact of sex steroids, epigenetic regulation of the X 
chromosome, and the microbiome as possible mechanistic etiologies, a recent review on 
the topic reports, “The efficacy of vaccines recommended for older-aged adults is 
consistently greater for females than for males.” Additionally, the autotransplant variable 
requires further investigation and possibly an entirely separate study looking just at 
vaccine efficacy in patients who undergo an autotransplant. These results suggest that 
patients that have had an autotransplant are significantly less likely to lose seroprotection 
by the end of the study. This model controls for disease stage, so the more durable 
response in patients that have undergone autotransplant cannot be attributed to the stage 
of their disease (early vs. advanced). Additionally, the relevant question is not just if the 
patient received a transplant, but when exactly that transplant occurred. It has been shown 
that the efficacy of a vaccine in this setting is influenced by the time elapsed since 
transplantation, the nature of the hematopoietic graft, the use of serial immunization, and 




that enrolled only patients who had undergone autotransplant would be needed to 
determine which clinical variables impact vaccine efficacy in plasma cell dyscrasia 
patients, as only 24% of patients in this study underwent an autotransplant in the past. 
Finally, the analysis of how HAI titer levels early in the flu season correlate with 
the loss of seroprotection by the end of the flu season yielded interesting results that may 
be clinically relevant. Figure 14 (page 40) demonstrates that patients who were 
seroprotected against all three strains at baseline were significantly less likely to lose 
seroprotection by the end of the study. It is not possible for patients to have their HAI 
titer levels checked before each flu season, but it is possible to determine which patients 
received the flu vaccine the prior year and are thus more likely to be protected at baseline 
and thus less likely to lose that protection by season’s end.  
The SHIVERING trials represent an important investigation into a novel 
influenza vaccine regimen in patients with plasma cell dyscrasias. This regimen of a 
high-dose vaccine followed by a booster is safe and the results from a randomized, 
double blind, placebo-controlled, experimental trial suggest that it is more efficacious 
than the standard of care with regard to protecting against flu infections and sparking a 
robust and durable serologic defense for these vulnerable patients with plasma cell 
dyscrasias. In addition to improved efficacy over the standard of care, these trials suggest 
several demographic and clinical correlates that are associated with improved or impaired 
response to this novel vaccine strategy. Finally, the analysis of serologic timing 
represents the first detailed investigation into when patients with plasma cell dyscrasias 
develop and lose protection, what clinical or demographic factors impact this timing, and 




The SHIVERING trials are an initial investigation into a growing field of research 
on vaccine efficacy in patients with cancer. These results will not immediately change 
clinical practice, but will hopefully move the needle toward using this high-dose booster 
regimen in patients with plasma cell dyscrasias. Morbidity from the influenza virus will 
likely continue to rise, with a record number of cases already occurring during the 2017 
to 2018 season, and more such research is required to better protect vulnerable and 
healthy people from this dangerous virus. There are countless directions in which this 
research could be expanded upon in the future. First, a much larger study population is 
necessary to prove superiority of this regimen. The trial that led to the approval of the 
high-dose vaccine in people above the age of 65 enrolled 31,989 participants over two 
years across 126 health centers in the United States and Canada.24 Second, about 80% of 
the patients in each SHIVERING study were receiving therapy at the time of the trial, and 
these therapies undoubtedly impact the patient’s vaccine response. Each patient was on a 
combination of immunomodulatory drugs, steroids, cytotoxic chemotherapies, and 
proteasome inhibitors, in addition to their non-cancer related therapies. It is possible 
patients should not receive a vaccine on the same day they receive cancer therapies or 
steroids. This seems reasonable but in practice most patients try to batch their reasons for 
coming to the hospital. This question of vaccine timing in relation to anti-cancer 
treatment should be investigated further. Third, as discussed previously, the impact of 
stem cell transplant timing on vaccine response should be more clearly defined. Such a 
study would impact patients not just with plasma cell dyscrasias, but those with all 




this trial suggest that there is a significant difference but the optimal time interval 
between transplant and vaccines should be studied.  
These are just a few of many additional questions that could be asked of this 
regimen and potential vaccine strategies in patients with plasma cell dyscrasias. The 
SHIVERING trials have pushed the envelope of how to vaccinate vulnerable, 
immunocompromised patients, but much work remains to be done before our influenza 
vaccine meet our patients’ needs.  
There are several key strengths of this work and several weaknesses that must be 
recognized. The primary strength is the methodology of SHIVERING 2. A randomized 
trial allows us to avoid selection bias, a placebo-controlled trials allows us to avoid bias 
from confounding factors, and the double-blinded set up avoided interpretation bias. 
Following the pilot trial of SHIVERING 1, which studied the safety and preliminary 
results of the new regimen, the randomized trial was the next step and represents the gold 
standard for determining superiority of a new regimen and is the cornerstone of 
evidenced-based medicine. 33  Additionally, the novel regimen as used in this unique 
patient population represents a key strength of this study and why this work will be of 
immediate interest to both patients and providers in the hematology community. Finally, 
the strength is in the data. Each patient in both trials was tracked closely throughout the 
trial periods, interviewed by a member of the trial team at each trial visit, and all data 
collected from the patient was cross-checked with their electronic medical record.   
The primary weakness of this study is its size. It was difficult to enroll more than 
five or six patients in a day given the need to process each sample immediately. 




flu vaccines immediately upon their availability and before hearing about the trial. It will 
take a multi-center, and multi-year study that further supports these results to elevate 
them to the height of clinical practice. Additionally, some might criticize our decision to 
randomize in a 2:1 distribution rather than a 1:1 distribution. This was done to increase 
the number of patients receiving the experimental regimen, but could be interpreted as 
evidence that the study team deemed our regimen to be superior from the start. However, 
these concerns represent the general systematic realities of designing a specified trial 
which required the collection of a large number of patients in a very limited period of 
time. In sum, this work represents a very strong effort and an interesting addition to the 
literature of plasma cell dyscrasias and vaccine efficacy. I hope it will trigger a passion 
for both fields in those who read it, as it has for the writer, and one day impact this 
















1. PBMC Protocol – per Lin Zang of the Dhodapkar Lab 
1. Peripheral blood (sodium heparin tube). Store blood tube(s) at room temperature 
if they cannot be processed immediately. 
2. Prepare 50 ml tubes with 10 ml of Ficoll-Hypaque. Gently layer approx. 15 - 20 
ml blood over F-H. Do not dilute blood to collect the plasma later. 
3. Centrifuge the tubes at 2000 rpm for 25 min at RT with brake off. 
4. Mononuclear leukocytes (MNL) should band in the middle of the tube. Using a 
10ml pipette, gently collect the supernatant (Plasma) to within 0.5 cm of the cell 
layer to a 15ml tube. Collect cells into new 50 ml tube adding RPMI Medium to a 
total volume of 40-50ml. 
5. Centrifuge at 1500 rpm, 10 min at 4 ˚C or RT. 
6. Discard sup, gently re-suspend pellet with 2-5 ml cell culture medium (5% 
PHS/RPMI). Count cells with Trypan blue (10ul cell suspension + 10ul Trypan 
Blue). 
7. Adding medium to the cell suspension tube to total of 20-25ml. Centrifuge at 
1300 rpm for 6 min. at 4 ˚C. 
8. If cells are to be used fresh: Re-suspend the cells as per protocol. 
9. If PBMCs are to be cryopreserved: Prepare fresh reagent: 10% DMSO/FBS for 
cryopreservation while tubes are centrifuging. 
10.  Re-suspend PBMCs with the cryopreserving solution at 5 x 106 /ml 
11.  Immediately dispense cells into labeled cryovials. 
12.  Place the cryovials in a freezing container that has been filled with 70 % 
isopropanol according to the manufacturer’s instructions. Store the freezing 
container at –80oC Freezer up to a week. 
13.  Transfer the cryopreservation of PBMCs into Liquid N2 Tank for long. term 
storage. 











2. HAI Titer Protocol (as described in our published paper): sera were treated with 
a receptor destroying enzyme, Vibrio cholera filtrate (Sigma-Aldrich, St. Louis, 
MO), which eliminates nonspecific inhibitors that could confound the assay 
results. Working stocks for each of the 3 current influenza virus strains included 
in the clinical trial influenza vaccine were prepared by diluting the virus stock to a 
final HA titer of 8 HA units per 50 mL. Two-fold dilutions of the receptor-
destroying enzyme- treated sera in buffer were then mixed with the working stock 
of each influenza virus strain. The serum virus samples were then incubated at 
room temperature for 30 minutes to allow any HA-specific antibodies present in 
the serum to neutralize the influenza virus. To each well, a 0.5% suspension of 
red blood cells was then added. The assay was then incubated on ice until the red 
blood cells in the buffer control sample formed a button and had agglutinated in 
the nonserum-containing control well. The HI titer is defined as the reciprocal of 
the highest dilution of serum that inhibits red blood cell agglutination. As defined 
previously,18 seroprotection to the influenza virus vaccine is based on achieving 
an antibody titer of 1:40, and seroconversion to the influenza virus vaccine is 














3. Flu morbidity screen questionnaire: the following questions were asked to each 
patient at each study visit and at the end of the study, either in person or over the 
phone. 
 
Flu Morbidity Screen Questions 
 
☐ During the study period, did the patient have any flu-like symptoms (fever, 
fatigue, headache, bodyache, cough, sore throat, fatigue)?    
 
☐ If yes, was the patient evaluated and tested for influenza?  
☐ Did the patient have a documented influenza infection during the study period?  
☐ Was the patient hospitalized as a result of an influenza infection? 
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